Tìm theo
Treprostinil
Các tên gọi khác (6 ) :
  • (1R,2R,3aS,9aS)-[[2,3,3a,4,9,9a-hexahydro-2-hydroxy- 1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl] oxy]acetic acid
  • [[(1R,2R,3aS,9aS)-2-Hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphtalen-5-yl]oxy]acetic acid
  • Treprostinil
  • Treprostinilo
  • Treprostinilum
  • Uniprost
antithrombins, anticoagulants
Thuốc Gốc
Small Molecule
CAS: 81846-19-7
ATC: B01AC21
ĐG : Baxter International Inc. , http://www.baxter.com
CTHH: C23H34O5
PTK: 390.5131
Treprostinil is a synthetic analogue of prostacyclin, used to treat pulmonary hypertension. Treprostinil is marketed as Remodulin®. [Wikipedia]
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C23H34O5
Phân tử khối
390.5131
Monoisotopic mass
390.240624198
InChI
InChI=1S/C23H34O5/c1-2-3-4-7-17(24)9-10-18-19-11-15-6-5-8-22(28-14-23(26)27)20(15)12-16(19)13-21(18)25/h5-6,8,16-19,21,24-25H,2-4,7,9-14H2,1H3,(H,26,27)/t16-,17-,18+,19-,21+/m0/s1
InChI Key
InChIKey=PAJMKGZZBBTTOY-ZFORQUDYSA-N
IUPAC Name
2-{[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-1H,2H,3H,3aH,4H,9H,9aH-cyclopenta[b]naphthalen-5-yl]oxy}acetic acid
Traditional IUPAC Name
treprostinil
SMILES
[H][C@]12C[C@@H](O)[C@H](CC[C@@H](O)CCCCC)[C@@]1([H])CC1=C(C2)C(OCC(O)=O)=CC=C1
Độ hòa tan
Insoluble at 25°C
logP
4.1
logS
-4.7
pKa (strongest acidic)
3.76
pKa (Strongest Basic)
-1.3
PSA
86.99 Å2
Refractivity
108 m3·mol-1
Polarizability
45.74 Å3
Rotatable Bond Count
10
H Bond Acceptor Count
5
H Bond Donor Count
3
Physiological Charge
-1
Number of Rings
3
Bioavailability
1
Rule of Five
true
Ghose Filter
true
MDDR-Like Rule
true
Dược Lực Học : Pulmonary arterial hypertension (PAH) is a disease in which blood pressure is abnormally high in the arteries between the heart and lungs. PAH is characterized by symptoms of shortness of breath during physical exertion. The condition can ultimately lead to heart failure. Treprostinil is a potent oral antiplatelet agent. The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation. In animals, the vasodilatory effects reduce right and left ventricular afterload and increase cardiac output and stroke volume. Other studies have shown that treprostinil causes a dose-related negative inotropic and lusitropic effect. No major effects on cardiac conduction have been observed.
Cơ Chế Tác Dụng : Treprostinil is a synthetic analogue of prostacyclin, used to treat pulmonary hypertension. Treprostinil is marketed as Remodulin®. [Wikipedia] The major pharmacological actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation. In addition to treprostinil's direct vasodilatory effects, it also inhibits inflammatory cytokine. As a synthetic analogue of prostacyclin, it binds to the prostacyclin receptor, which subsequently induces the aforementioned downstream effects.
Dược Động Học :
▧ Absorption :
Relatively rapid and complete after subcutaneous infusion, with an absolute bioavailability approximately 100%. In patients with mild (n=4) or moderate (n=5) hepatic insufficiency and portopulmonary hypertension following a subcutaneous dose of 10 ng per kg of body weight per min for 150 mins the AUC 0-∞ was increased 3-fold and 5-fold respectively.
▧ Volume of Distribution :
* 14 L/70 kg
▧ Protein binding :
Human plasma protein binding is approximately 91% in in vitro concentrations ranging from 330 to 10,000 µ/L.
▧ Metabolism :
Substantially metabolized by the liver, but the precise enzymes responsible are unknown. Five metabolites have been described (HU1 through HU5) however, the biological activity and metabolic fate of these are unknown. The chemical structure of HU1 is unknown. The metabolite HU5 is the glucuronide conjugate of treprostinil. The other metabolites are formed by oxidation of the 3-hydroxyoctyl side chain (HU2) and subsequent additional oxidation (HU3) or dehydration (HU4). Study results of in vitro human hepatic cytochrome P450 demonstrates that treprostinil does not inhibit CYP-1A2, 2C9, 2C19, 2D6, 2E1, or 3A. Whether treprostinil induces these enzymes has not been studied.
▧ Half Life :
Terminal elimination half-life is approximately 2 to 4 hours. Plasma half-life is 34 and 85 minutes for intravenous and subcutaneous infusion of the drug, respectively.
Độc Tính : Symptoms of overdose are extensions of its dose-limiting pharmacologic effects and include flushing, headache, hypotension, nausea, vomiting, and diarrhea. Most events were self-limiting and resolved with reduction or withholding of treprostinil.
Chỉ Định : For use as a continuous subcutaneous infusion or intravenous infusion (for those not able to tolerate a subcutaneous infusion) for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise.
Tương Tác Thuốc :
  • Abciximab The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Abciximab. Monitor for increased bleeding during concomitant thearpy.
  • Acebutolol Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Acenocoumarol The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Acenocoumarol. Monitor for increased bleeding during concomitant thearpy.
  • Acetazolamide Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Acetylsalicylic acid The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Acetylsalicylic acid. Monitor for increased bleeding during concomitant thearpy.
  • Amiloride Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Aminosalicylic Acid The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the salicylate, Aminosalicylic acid. Monitor for increased bleeding during concomitant thearpy.
  • Amlodipine Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Amyl Nitrite Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Anagrelide The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Anagrelide. Monitor for increased bleeding during concomitant thearpy.
  • Apraclonidine Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Argatroban The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Argatroban. Monitor for increased bleeding during concomitant thearpy.
  • Atenolol Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Benazepril Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Bendroflumethiazide Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Betaxolol Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Bisoprolol Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Bivalirudin The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Bivalirudin. Monitor for increased bleeding during concomitant thearpy.
  • Brimonidine Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Bumetanide Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Candesartan Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Captopril Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Carteolol Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Carvedilol Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Celecoxib The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Celecoxib. Monitor for increased bleeding during concomitant thearpy.
  • Celiprolol Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Chlorothiazide Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Chlorthalidone Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Cilazapril Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Cilostazol The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Cilostazol. Monitor for increased bleeding during concomitant thearpy.
  • Citalopram The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Citalopram. Monitor for increased bleeding during concomitant thearpy.
  • Clevidipine Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Clonidine Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Clopidogrel The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Clopidogrel. Monitor for increased bleeding during concomitant thearpy.
  • Cyclandelate Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Dexmedetomidine Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Diclofenac The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Diclofenac. Monitor for increased bleeding during concomitant thearpy.
  • Diclofenamide Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Diflunisal The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Diflunisal. Monitor for increased bleeding during concomitant thearpy.
  • Diltiazem Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Dipyridamole The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Dipyridamole. Monitor for increased bleeding during concomitant thearpy. Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Doxazosin Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Drospirenone Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Drotrecogin alfa The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Drotrecogin alfa. Monitor for increased bleeding during concomitant thearpy.
  • Enalapril Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Enoxaparin The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Exoxaparin. Monitor for increased bleeding during concomitant thearpy.
  • Eplerenone Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Eprosartan Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Eptifibatide The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Eptifibatide. Monitor for increased bleeding during concomitant thearpy.
  • Escitalopram The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Escitalopram. Monitor for increased bleeding during concomitant thearpy.
  • Esmolol Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Ethacrynic acid Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Etodolac The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Etodolac. Monitor for increased bleeding during concomitant thearpy.
  • Felodipine Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Fenoprofen The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Fenoprofen. Monitor for increased bleeding during concomitant thearpy.
  • Fluoxetine The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Fluoxetine. Monitor for increased bleeding during concomitant thearpy.
  • Flurbiprofen The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Flurbiprofen. Monitor for increased bleeding during concomitant thearpy.
  • Fluvoxamine The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Fluvoxamine. Monitor for increased bleeding during concomitant thearpy.
  • Fosinopril Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Furosemide Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Guanabenz Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Guanfacine Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Heparin The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Heparin. Monitor for increased bleeding during concomitant thearpy.
  • Hydralazine Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Hydrochlorothiazide Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Hydroflumethiazide Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Ibuprofen The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Ibuprofen. Monitor for increased bleeding during concomitant thearpy.
  • Indapamide Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Indomethacin The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Indomethacin. Monitor for increased bleeding during concomitant thearpy.
  • Irbesartan Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Isosorbide Dinitrate Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Isosorbide Mononitrate Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Isradipine Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Ketoprofen The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Ketoprofen. Monitor for increased bleeding during concomitant thearpy.
  • Ketorolac The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Ketorolac. Monitor for increased bleeding during concomitant thearpy.
  • Labetalol Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Lepirudin The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Lepirudin. Monitor for increased bleeding during concomitant thearpy.
  • Levobunolol Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Lisinopril Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Losartan Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Lumiracoxib The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Lumiracoxib. Monitor for increased bleeding during concomitant thearpy.
  • Mannitol Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Meclofenamic acid The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Meclofenamate. Monitor for increased bleeding during concomitant thearpy.
  • Mefenamic acid The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Mefenamic acid. Monitor for increased bleeding during concomitant thearpy.
  • Meloxicam The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Meloxicam. Monitor for increased bleeding during concomitant thearpy.
  • Methazolamide Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Methyclothiazide Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Metipranolol Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Metolazone Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Metoprolol Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Minoxidil Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Moexipril Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Nabumetone The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Nabumetone. Monitor for increased bleeding during concomitant thearpy.
  • Nadolol Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Naproxen The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Naproxen. Monitor for increased bleeding during concomitant thearpy.
  • Nebivolol Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Nesiritide Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Nicardipine Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Nifedipine Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Nimodipine Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Nisoldipine Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Nitrendipine Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Nitroglycerin Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Nitroprusside Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Olmesartan Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Oxaprozin The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Oxaprozin. Monitor for increased bleeding during concomitant thearpy.
  • Oxprenolol Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Papaverine Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Paroxetine The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Paroxetine. Monitor for increased bleeding during concomitant thearpy.
  • Penbutolol Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Perindopril Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Phenoxybenzamine Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Phentolamine Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Pindolol Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Piroxicam The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Piroxicam. Monitor for increased bleeding during concomitant thearpy.
  • Polythiazide Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Prazosin Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Quinapril Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Ramipril Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Reserpine Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Rivaroxaban The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Rivaroxaban. Monitor for increased bleeding during concomitant thearpy.
  • Salsalate The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the salicylate, Salsalate. Monitor for increased bleeding during concomitant thearpy.
  • Sertraline The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Sertraline. Monitor for increased bleeding during concomitant thearpy.
  • Sotalol Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Spironolactone Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Sulindac The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Sulindac. Monitor for increased bleeding during concomitant thearpy.
  • Telmisartan Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Terazosin Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Tiaprofenic acid The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Tiaprofenic acid. Monitor for increased bleeding during concomitant thearpy.
  • Ticlopidine The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Ticlopidine. Monitor for increased bleeding during concomitant thearpy.
  • Timolol Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Tirofiban The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Tirofiban. Monitor for increased bleeding during concomitant thearpy.
  • Tizanidine Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Tolazoline Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Tolmetin The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Tolmetin. Monitor for increased bleeding during concomitant thearpy.
  • Torasemide Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Trandolapril The prostacyclin analogue, Treprostinil, may increase the hypotensive effect of Trandolapril.
  • Triamterene Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Trichlormethiazide Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Urea Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Valsartan Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Verapamil Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Warfarin The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Warfarin. Monitor for increased bleeding during concomitant thearpy.
Liều Lượng & Cách Dùng : Solution - Intravenous
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
  • Công ty :
    Sản phẩm biệt dược : Orenitram
  • Sản phẩm biệt dược : Remodulin
  • Sản phẩm biệt dược : Tyvaso
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00374
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/66302-206-01
PharmGKB
http://www.pharmgkb.org/drug/PA164768801
Wikipedia
http://en.wikipedia.org/wiki/Treprostinil
RxList
http://www.rxlist.com/cgi/generic/remodulin.htm
Drugs.com
http://www.drugs.com/cdi/treprostinil-inhalation-solution.html
... loading
... loading